Directors

Alan Yu, Chairman of the Board of Directors, is the Vice President and Chief Operating Officer of the CKLS Group responsible for the commercial activities of the Group, including manufacturing and marketing of all product applications.  Mr. Yu has held a number of positions in multinational corporations, including Standard Chartered Bank, Dairy Farm and American Express, in Hong Kong and overseas.  Prior to joining the Group in January 2000, he was a Worldwide Vice President with Johnson & Johnson.  Mr. Yu holds a Bachelor of Arts degree and a Master’s degree in Business Administration. 

Dr. John W. Sibert III is Managing Partner at GFG China Partners LLC, a company evaluating opportunities and investing in the China expansion of later-stage US technology companies, primarily focused on energy/environment and biotech/pharma.  Dr. Sibert was formerly President and Managing Partner, Triton Innovations Group, LLC, a Limited Liability Corporation of the State of California.  Dr. Sibert served as Vice President and Chief Operating Officer and Executive Director, Technology Transfer and Industry Collaboration – California State University Institute, responsible for commercialization of technology developed on the 23 campuses of the CSU and joint development efforts in partnership with the private sector and government.  He was also responsible for technology transfer operations for the California State University system as well as development of research and development partnerships between the university faculty and industry.  Dr. Sibert was the Founding Executive Director of the Alaska Science & Technology Foundation, responsible for the operations of the $100,000,000 Foundation, including the supervision of the support staff and management of facilities.  Dr. Sibert served as California Institute of Technology (Caltech) Division Administrator, Chemistry & Chemical Engineering managing staff, services, and facilities for a division of 480 people and, prior to that, as Manager of Exploratory and Program Research, Atlantic Richfield Company, managing a variety of research programs and the Corporate Resources Technology Laboratory.  Dr. Sibert was an Assistant Professor at Yale University, Department of Chemistry, and conducted research on model systems for metalloenzymes, environmental impact of metals, and mechanisms of redox reactions of organometallics. Dr. Sibert holds or has held the following positions: Director and Founding Chairman, National Association of Seed & Venture Funds; Member, State of California Capital Formation and Business Development Committee; Member, Board of Trustees, Claremont Graduate University; Member, Board of Advisors, NASA Technology Commercialization Center – JPL/Dryden; Vice President and Member of the Board of Directors of Maxdem Inc. (now Mississippi Polymer Technologies, Inc.), Member, Board of Directors, Los Angeles Regional Technology Alliance; Member, Science & Technology Council of the States, National Governors’ Association, Chair of the Best Practices Committee, Washington, DC; Member, Board of Visitors, Department of Chemistry, University of Tennessee; Member, Board of Advisors, Department of Chemistry and Adjunct Professor, University of Texas, Dallas.  His consulting activities include National Governors Association; Oklahoma Council for the Advancement of Science & Technology; Ohio Department of Development; Chugash Electric Company; National Technology Transfer Center, NASA; Kentucky Science & Technology Corporation NASA SBIR program; JPL Technology Commercialization Program; Ensci Inc., Woodland Hills, California; Harding Lawson Associates, Denver, Colorado; Air and Water Pollution Subcommittee, US Senate; Subcommittee on Consumer Protection and Finance, US House of Representatives.  Dr. Sibert has a Ph.D. in Bioinorganic Chemistry from the University of California, San Diego and a BS and MS in Chemistry from the South Dakota School of Mines and Technology.  He has 15 patents and numerous publications. He was honourably discharged from the United States Marine Corps.

Kenneth M. Strong is currently the President and CEO, S3Holdings, Inc. (S3), Ottawa, Canada and Beijing, China.  S3 was created to develop, mainly through its affiliate, Cosmos International, business opportunities and provide strategic services to Chinese and international companies in the technology, health care, real estate, transportation, environment and energy sectors in China.  Over the past 15 years, Mr. Strong has focused primarily on technology-related venture capital investment, where he developed strong and continuing relationships with leading research-based institutions such as Massachusetts Institute of Technology and Harvard Medical School. Mr. Strong has led in the creation and development of numerous technology-based enterprises, serving in director and/or Chairman capacities as well as founding management, and helping these companies in the raising of in excess of $250mm in private and institutional investment capital.  Earlier in his career, Mr. Strong served for three years as Special Assistant to the Prime Minister of Canada.  Mr. Strong’s broad experience internationally includes service with the World Economic Forum and the United Nations, where he helped in the organization of major international events such as the World Economic Forum annual meeting in Davos, Switzerland and the Earth Summit in Rio de Janeiro.  Mr. Strong completed his early schooling in Ottawa, Canada and Nyon, Switzerland, and attended Carleton University and the University of Ottawa.

Guang (Michael) Luan has been involved in numerous successful real estate developments and is an investor and the co-coordinator of a syndicated US$50 million bond fund in the United States.  Until May 2005 Mr. luan was the Chairman and CEO of Beijing Fushuntai Investment Management Co. Ltd., a private investment company that makes strategic investments in various international ventures and has been a director of several public companies over the past 10 years.

Simon Anderson is a chartered accountant with over 19 years experience in the financial markets.  Mr. Anderson brings extensive expertise to WEX in the areas of corporate finance, financial consulting, mergers and acquisitions and securities markets valuation. For the last eight years, Mr. Anderson has been Vice-President of MCSI Consulting Services Inc., a company that provides consulting expertise in the areas of regulatory compliance, exchange listings, securities valuation and financial operations. Previously, he was with BDO Dunwoody Chartered Accountants and Consultants, and with Collins, Barrow Chartered Accountants. Currently, Mr. Anderson is also a board member and/or chief financial officer for a number of publicly traded companies trading on the TSX, TSX-V and AMEX exchanges.

Dr. Tom Du has extensive experience in drug development and has held product development responsibility in various therapeutic areas including oncology, pulmonary/allergy, rheumatology, inflammatory and lipid-lowering indications. He has worked either as project leader or a project team member to help various American, European and Asian drug manufacturers develop their products in the United States and Asia. Dr. Du has also worked as a consultant to the financial industry in the United States to evaluate the product/business potential of small pharmaceutical companies.   Prior to joining Humphries, he worked as Senior Director, Clinical and Regulatory Affairs, Hutchison Medipharma — a Hutchison Whampoa Company. Dr. Tom Du is a physician and also a scientist. He graduated from Tianjin Medical University (TMU). He received his trainings in internal medicine at TMU and in pathology at McGill University. Before joining the US Food and Drug Administration (FDA) as a reviewing officer in 1994, he had two years of fellowship training at Harvard University. While with the FDA, Dr. Du reviewed more than one hundred INDs and NDAs. Since resigning from the FDA in 2000, he has held several important positions in the pharmaceutical industry. He was Acting Managing Director, China Operations, and subsequently Senior Director, Global Regulatory Affairs at Ingenix Pharmaceutical Services - a United Health Group Company.

Victor Tong is the Chief Financial Officer of CK Life Sciences (North America) Inc.  Mr. Tong oversees the accounting, financial reporting and financial management functions of all the North American subsidiaries and investee companies of the CKLS Group.  Prior to joining the Group, he spent over 18 years in investment banking in Canada, primarily with global firms such as BMO Nesbitt Burns, HSBC and Deloitte.  Mr. Tong holds a Bachelor of Business Administration degree and a Master of Business Administration degree.  He is also qualified as a professional accountant in the Province of Ontario.